Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.
Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),
Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.
Disclosures: The study was supported by the Swedish Research Council, the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.
Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.